Improving Molecular Biomarker Reporting

Molecular biomarker reports often rely on healthcare providers knowing the significance of a specific somatic variant in a particular disease, and what drug targets/therapies may be efficacious. Providing a user-friendly biomarker report which effectively communicates variant clinical significance in the context of disease, other variants, and level of evidence supporting variant impact on pathogenicity is challenging. Best practices are needed for biomarker and molecular profiling result reporting for efficient interpretation. This provides better diagnostic guidance for oncologists and optimal information for all healthcare professionals caring for patients with cancer. AMP has led other efforts to standardize oncology variant interpretation and reporting guidelines and molecular laboratory practice in collaboration with other professional organizations and interest holder representatives. 

"Provider-friendly” Molecular Biomarker Reports  

AMP convened a subject matter expert working group with representation from American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) to develop a consensus provider-friendly (i.e., “oncologist-friendly”) next-generation sequencing (NGS) molecular biomarker report template focused on specific report elements, including format and content details. See 'Developing Consensus for a More Provider-Friendly Next Generation Sequencing Molecular Biomarker Report: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists' published in The Journal of Molecular Diagnostics (JMD) for complete project details. 

Provider-Friendly NGS Molecular Biomarker Report Template 

Example of a non-small cell lung cancer report using the Provider-Friendly NGS Report Template 

Help us implement & improve the "Provider-friendly” Molecular Biomarker Reports template 

An implementation survey will follow on-demand CME education about the provider-friendly molecular biomarker report template in one year to determine community template uptake. The team will revise the template based on this feedback and communicate survey findings to the public.  

REGISTER FOR THE LIVE WEBCAST & PARTICIPATE (CME available)

VIEW THE ON DEMAND WEBINAR & PARTICIPATE (CME available for 1 year)  

Watch the 2023 AMP Annual Meeting & Expo Session (non-CME) 

This project is supported by unrestricted educational grant funding  

from AstraZeneca and Daiichi Sanyko, Inc.